Document Detail

Monoaminergic effects of folinic acid, L-DOPA, and 5-hydroxytryptophan in dihydropteridine reductase deficiency.
MedLine Citation:
PMID:  7760062     Owner:  NLM     Status:  MEDLINE    
Plasma and CSF concentrations of endogenous L-DOPA, catecholamines, and metabolites of monoamines were assayed in a patient with atypical phenylketonuria due to absent dihydropteridine reductase (DHPR), before and during treatment with folinic acid, Sinemet, and 5-hydroxytryptophan. The patient had low but detectable levels of L-DOPA, 3,4-dihydroxyphenylacetic acid (DOPAC), and 3,4-dihydroxyphenylglycol (DHPG) in plasma and low but detectable levels of these compounds and of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) in CSF, with approximately normal plasma and CSF levels of norepinephrine [noradrenaline (NA)]. Folinic acid treatment approximately doubled plasma levels of L-DOPA, NA, DOPAC, and DHPG, compared with values during dietary phenylalanine restriction alone. Detection of L-DOPA, catecholamines, and monoamine metabolites in this patient indicates that monoamine synthesis in humans does not absolutely require DHPR. The results are consistent with the existence of an alternative biochemical pathway, with folinic acid treatment augmenting activity along this pathway. Low plasma levels of L-DOPA, DOPAC, and DHPG may reflect decreased catecholamine synthesis and turnover in sympathetic nerves, with compensatory increases in exocytotic release normalizing plasma NA levels.
D S Goldstein; S H Hahn; C Holmes; C Tifft; J Harvey-White; S Milstien; S Kaufman
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of neurochemistry     Volume:  64     ISSN:  0022-3042     ISO Abbreviation:  J. Neurochem.     Publication Date:  1995 Jun 
Date Detail:
Created Date:  1995-06-28     Completed Date:  1995-06-28     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  2985190R     Medline TA:  J Neurochem     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2810-3     Citation Subset:  IM    
Clinical Neuroscience Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
5-Hydroxytryptophan / therapeutic use*
Biogenic Monoamines / metabolism*
Leucovorin / therapeutic use*
Levodopa / therapeutic use*
Reg. No./Substance:
0/Biogenic Monoamines; 0/Levodopa; 56-69-9/5-Hydroxytryptophan; 58-05-9/Leucovorin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Inhibition of striatal GABA release by the adenosine A2a receptor is not mediated by increases in cy...
Next Document:  Molecular characterization of a type II cyclic GMP-dependent protein kinase expressed in the rat bra...